Author

Mary E. Keir 1

1 Genentech Inc., South

CROSS-SPECIES TRANSLATABILITY OF NONCLINICAL SAFETY ASSESSMENTS OF A HUMAN INTERLEUKIN-22FC, AN IG FUSION PROTEIN FOR THE POTENTIAL TREATMENT OF INFECTIOUS OR INFLAMMATORY DISEASES

Donna W. Lee, Shelly Zhong, Rama Pai, Estelle Doudement, Eric Stefanich, Julie Rae, Johnny Gutierrez, Jeff Lutman, Xiaoting Wang, Annemarie Lekkerkerker, Julia Qiu, Kelly Loyet, Ann Herman, Wenjun Ouyang, Mary E. Keir, Dimitry Danilenko

ETROLIZUMAB TREATMENT DOES NOT MODIFY LEVELS OF VCAM-1 IN ULCERATIVE COLITIS PATIENTS

Franklin Fuh, C Looney, Wei Tew, R Erickson, Romeo Maciuca, Meina Tang, Mary E. Keir, Severine Vermeire, Teresa Ramirez Montagut

ETROLIZUMAB TREATMENT MODULATES MADCAM-1 LEVELS IN SERUM IN ULCERATIVE COLITIS PATIENTS

Franklin Fuh, R Erickson, C Schofield, Meina Tang, Romeo Maciuca, Mary E. Keir, Severine Vermeire, Teresa Ramirez Montagut

Greater Reductions of Gut T Lymphocytes with Combined Blockade of α4β7 and αEβ7 Integrins Versus Individual Blockade Alone

Bingbing Dai, Ryan Ichikawa, Justin Elstrott, Alvin Gogineni, Mary E. Keir, Jacqueline McBride, Tangsheng Yi

INCREASED EXPRESSION OF T-CELL-ASSOCIATED GENES IN BASELINE BIOPSIES FROM TNF ANTAGONIST NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO UNDERGO REMISSION IN RESPONSE TO ETROLIZUMAB IN A PHASE II TRIAL

Gaik Tew, Jason Hackney, Deena Gibbons, Christopher Andrew Lamb, Diana Luca, Jackson Egen, Severine Vermeire, John Charles Mansfield, Brian G. Feagan, Julian Panés, Daniel C. Baumgart, Stefan Schreiber, Iris Dotan, William Sandborn, John A. Kirby, Peter Irving, Gert De Hertogh, Gert Van Assche, Paul Rutgeerts, Sharon O'B

PHARMACOLOGY OF ETROLIZUMAB IN A PHASE 2 STUDY IN MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS

Marna Williams, Mary E. Keir, Caroline Looney, Franklin Fuh, Wei Tew, Kathleen Howell, Sha Klabunde, Clarissa Johnson, Xiaohui Wei, Meina Tang, Diana Luca, Azucena Salas, Severine Vermeire, Clementine Perrier, Julian Panés, Daniel C. Baumgart, John Charles Mansfield, Maren Paulsen, Philip Rosenstiel, Stefan Schreiber, I

PHARMACOLOGY OF ETROLIZUMAB IN A PHASE 2 STUDY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Caroline Looney, Franklin Fuh, Meina Tang, Xiaohui Wei, Mary E. Keir, Gaik Tew, Jeffrey Eastham-Anderson, Lauri Diehl, Azucena Salas, Gert De Hertogh, Steven Francom, Houston Gilbert, Diana Luca, Jackson Egan, Severine Vermeire, John Charles Mansfield, Christopher Andrew Lamb, Brian G. Feagan, Julian Panés, Daniel C. Bau

PRE-CLINICAL PHARMACOLOGY FOR A HUMAN INTERLEUKIN-22 IG FUSION PROTEIN FOR THE POTENTIAL TREATMENT OF INFECTIOUS OR INFLAMMATORY DISEASES

Eric Stefanich, Julie Rae, Jeff Lutman, Xiaoting Wang, Annemarie Lekkerkerker, Wenjun Ouyang, Julia Qiu, Donna W. Lee, Dimitry Danilenko, Kelly Loyet, Mary E. Keir, Siddharth Sukumaran, Ann Herman

Item 1 - 8 / 8
1